Malignant Pleural Mesothelioma Market: Epidemiology, Therapies, Companies, DelveInsight | Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, PharmaMar, AstraZeneca, Targovax, TCR2 Therapeutics, Hoffmann-La Roche

Malignant Pleural Mesothelioma therapies, such as KEYTRUDA (Pembrolizumab), OPDIVO (Nivolumab) and YERVOY (Ipilimumab), Volrustomig (MEDI5752), Pegargiminase with Pemetrexed and Cisplatin, MesoPher, and others, are expected to boost the Malignant Pleural Mesothelioma Market in the upcoming years.

DelveInsight has launched a new report on "Malignant Pleural Mesothelioma - Market Insights, Epidemiology, and Market Forecast-2034" that delivers an in-depth understanding of the Malignant Pleural Mesothelioma, historical and forecasted epidemiology as well as the Malignant Pleural Mesothelioma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Discover about the Malignant Pleural Mesothelioma market report @ https://www.delveinsight.com/report-store/inflammatory-myositis-im-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Some of the key facts of the Malignant Pleural Mesothelioma Market Report:

The Malignant Pleural Mesothelioma (MPM) market is expected to experience gradual growth throughout the forecast period (2025-2034), driven by the introduction of novel treatment options such as volrustomig (MEDI5752), KEYTRUDA with cisplatin/pemetrexed, pegargiminase with pemetrexed and cisplatin, mesopher, and galinpepimut-S.
In September 2024, the FDA approved pembrolizumab (Keytruda) in combination with pemetrexed and platinum-based chemotherapy as the first-line treatment for unresectable advanced or metastatic MPM. This approval, based on data from the KEYNOTE-483 phase 2/3 trial, showed improved overall survival (median OS: 17.3 vs 16.1 months; HR 0.79, P = .0162) and a higher response rate (52% vs 29%) compared to chemotherapy alone
DelveInsight estimates that in 2024, approximately 11,400 mesothelioma cases were reported across the 7MM. However, this number is projected to decline by 2034, with a negative CAGR of 0.3%. Despite this, the MPM market value is expected to increase modestly, from around USD 210 million in 2024, with a forecasted CAGR of 0.7% during 2025-2034.
Leading pharmaceutical companies in the MPM space include Bristol-Myers Squibb, Ono Pharmaceuticals, Merck, and Novocure, offering therapies such as OPDIVO (nivolumab) with YERVOY (ipilimumab), OPDIVO monotherapy, KEYTRUDA in combination with pemetrexed, and the OPTUNE LUA device.
MPM remains a difficult-to-diagnose cancer due to its non-specific symptoms and long latency period, which often results in late-stage diagnoses. While advanced imaging techniques and biomarker research offer some promise, current diagnostic tools remain inadequate, emphasizing the critical need for improved early detection strategies.
In 2024, around 11,400 mesothelioma cases were reported across the 7MM, with forecasts suggesting a gradual decline by 2034.
The United States accounted for approximately 2,250 new cases of Malignant Pleural Mesothelioma (MPM) that year-about 20% of the total incidence across these key markets.
In the EU4 and the UK, the disease was significantly more prevalent among males, with an estimated 5,000 cases, compared to approximately 1,400 cases in females, underscoring a clear gender-based disparity in incidence rates.
Key Malignant Pleural Mesothelioma companies such as Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, PharmaMar, AstraZeneca, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, and others are evaluating new drugs for Malignant Pleural Mesothelioma to improve the treatment landscape.
Promising Malignant Pleural Mesothelioma therapies include KEYTRUDA (Pembrolizumab), OPDIVO (Nivolumab) and YERVOY (Ipilimumab), Volrustomig (MEDI5752), Pegargiminase with Pemetrexed and Cisplatin, MesoPher, and others.

Malignant Pleural Mesothelioma Overview

Malignant Pleural Mesothelioma (MPM) is a highly aggressive cancer arising from the mesothelial cells of the pleura and is strongly associated with long-term asbestos exposure. It progresses rapidly and carries a high mortality rate, predominantly affecting older men, often appearing decades after initial exposure. The disease's significant tumor heterogeneity contributes to treatment resistance, making it difficult to manage effectively.

To improve diagnostic clarity, the 2021 WHO Classification of Thoracic Tumors by IARC introduced updated terminology-replacing "diffuse malignant pleural mesothelioma" with "diffuse pleural mesothelioma" and "localized malignant pleural mesothelioma" with "localized pleural mesothelioma."

Asbestos remains the primary risk factor, with inhaled fibers causing persistent inflammation and cellular injury over many years. Other contributing factors include exposure to minerals like erionite (a type of zeolite), previous radiation therapy, and possible viral links such as simian virus 40. Genetic predispositions-particularly BAP1 mutations-alongside age and male sex, also influence susceptibility.

Common symptoms include shortness of breath and chest pain, often caused by pleural effusion in early stages and tumor encasement of the lungs in later stages. Additional signs such as fatigue, weight loss, and malaise are largely due to inflammatory cytokine release. Rare complications like superior vena cava syndrome or difficulty swallowing may occur if the tumor invades nearby structures. Some individuals may remain asymptomatic for extended periods, highlighting the importance of ongoing surveillance in those with known asbestos exposure.

Malignant Pleural Mesothelioma Market Outlook

The treatment landscape for Malignant Pleural Mesothelioma (MPM) comprises surgery, radiotherapy, and chemotherapy, with chemotherapy continuing to be the primary standard of care. Given the aggressive progression of MPM, surgical intervention is typically limited to carefully selected patients, while radiotherapy is mainly used to alleviate symptoms.

Common chemotherapy regimens include drugs such as pemetrexed, cisplatin, gemcitabine, and carboplatin, which remain the most frequently employed treatment options in managing the disease.

Chemotherapy for Malignant Pleural Mesothelioma (MPM) is classified into first-line and second-line or beyond, depending on the disease stage and how the patient has responded to earlier treatments. Despite the available treatment options, each modality has its drawbacks-surgery is appropriate for only a small group of patients, radiotherapy is not curative, and chemotherapy often struggles with issues such as drug resistance and disease recurrence.

To address these limitations, several targeted therapies and immunotherapy agents have been approved, aiming to enhance treatment efficacy and improve survival outcomes for patients.

However, there remains a critical need for more effective therapies, as current first-line treatments offer limited durability and variable patient responses. A number of promising candidates are under development, including Volrustomig (MEDI5752), Pegargiminase in combination with Pemetrexed and Cisplatin, and MesoPher, among others. These investigational drugs represent hope for expanding the therapeutic arsenal against MPM.

Discover how the Malignant Pleural Mesothelioma market is rising in the coming years @ https://www.delveinsight.com/report-store/inflammatory-myositis-im-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Marketed Malignant Pleural Mesothelioma Drugs

KEYTRUDA (Pembrolizumab): Merck
OPDIVO (Nivolumab) and YERVOY (Ipilimumab): Bristol Myers Squibb/Ono Pharmaceuticals
OPDIVO (Nivolumab): Bristol Myers Squibb/Ono Pharmaceutical

Emerging Malignant Pleural Mesothelioma Drugs

Volrustomig (MEDI5752): AstraZeneca
Pegargiminase with Pemetrexed and Cisplatin: Polaris Pharmaceuticals
MesoPher: Amphera BV

Scope of the Malignant Pleural Mesothelioma Market Report
Study Period: 2020-2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Malignant Pleural Mesothelioma Companies: Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, PharmaMar, AstraZeneca, Targovax, TCR2 Therapeutics, Hoffmann-La Roche, and others
Key Malignant Pleural Mesothelioma Therapies: KEYTRUDA (Pembrolizumab), OPDIVO (Nivolumab) and YERVOY (Ipilimumab), Volrustomig (MEDI5752), Pegargiminase with Pemetrexed and Cisplatin, MesoPher, and others
Malignant Pleural Mesothelioma Therapeutic Assessment: Malignant Pleural Mesothelioma current marketed and Malignant Pleural Mesothelioma emerging therapies
Malignant Pleural Mesothelioma Market Dynamics: Malignant Pleural Mesothelioma market drivers and Malignant Pleural Mesothelioma market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Malignant Pleural Mesothelioma Unmet Needs, KOL's views, Analyst's views, Malignant Pleural Mesothelioma Market Access and Reimbursement

To know what's more in our Malignant Pleural Mesothelioma report, visit https://www.delveinsight.com/sample-request/inflammatory-myositis-im-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Key benefits of the Malignant Pleural Mesothelioma Market Report:
Malignant Pleural Mesothelioma market report covers a descriptive overview and comprehensive insight of the Malignant Pleural Mesothelioma Epidemiology and Malignant Pleural Mesothelioma market in the 7MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan).
The Malignant Pleural Mesothelioma market report provides insights into the current and emerging therapies.
The Malignant Pleural Mesothelioma market report provides a global historical and forecasted market covering drug outreach in 7MM.
The Malignant Pleural Mesothelioma market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Malignant Pleural Mesothelioma market.

Got queries? Click here to know more about the Malignant Pleural Mesothelioma market Landscape https://www.delveinsight.com/sample-request/inflammatory-myositis-im-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Table of Contents

1. Report Introduction
2. Executive Summary
3. SWOT analysis
4. Malignant Pleural Mesothelioma Patient Share (%) Overview at a Glance
5. Malignant Pleural Mesothelioma Market Overview at a Glance
6. Malignant Pleural Mesothelioma Disease Background and Overview
7. Malignant Pleural Mesothelioma Epidemiology and Patient Population
8. Country-Specific Patient Population of Malignant Pleural Mesothelioma
9. Malignant Pleural Mesothelioma Current Treatment and Medical Practices
10. Unmet Needs
11. Malignant Pleural Mesothelioma Emerging Therapies
12. Malignant Pleural Mesothelioma Market Outlook
13. Country-Wise Malignant Pleural Mesothelioma Market Analysis (2020-2034)
14. Market Access and Reimbursement of Therapies
15. Market drivers
16. Market barriers
17. Appendix
18. Malignant Pleural Mesothelioma Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Click here to read more about Malignant Pleural Mesothelioma Market Outlook 2034 https://www.delveinsight.com/report-store/inflammatory-myositis-im-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr

Related Reports:

Malignant Pleural Mesothelioma Pipeline Insights, DelveInsight

"Malignant Pleural Mesothelioma Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the Malignant Pleural Mesothelioma market. A detailed picture of the Malignant Pleural Mesothelioma pipeline landscape is provided, which includes the disease overview and Malignant Pleural Mesothelioma treatment guidelines.

Contact Info:

Kritika Rehani, Assistant Manager, Marketing & Branding
krehani@delveinsight.com
info@delveinsight.com
www.delveinsight.com
+14699457679

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.